Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings: inhaled TOBI® (IV preparation) vs tobramycin Antibiotic resistance · adults and children with CF and P aeruginosa Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: inhaled TOBI® (IV preparation) vs tobramycin Adverse events · adults and children with CF and P aeruginosa Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: tobramycin for inhalation powder vs tobramycin FVC · children and adults with CF and P aeruginosa Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: tobramycin for inhalation powder vs tobramycin Quality of life · children and adults with CF and P aeruginosa Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: aztreonam lysine for inhalation vs tobramycin FVC · children and adults with CF and P aeruginosa Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: amikacin liposome inhalation suspension (ALIS) vs tobramycin FVC · children and adults with CF and P aeruginosa Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: amikacin liposome inhalation suspension (ALIS) vs tobramycin Survival · children and adults with CF and P aeruginosa Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: levofloxacin for inhalation solution vs tobramycin Survival · adults and children aged over 12 with CF and P aeruginosa Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: continuous cycles alternating aztreonam lysine for inhalation with tobramycin for inhalation solution vs continuous cycles alternating placebo with tobramycin FVC · children and adults with CF and P aeruginosa Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: continuous cycles alternating aztreonam lysine for inhalation with tobramycin for inhalation solution vs continuous cycles alternating placebo with tobramycin Survival · children and adults with CF and P aeruginosa Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Support plus vs usual care Stopping breastfeeding (any) at 9 months ‐ not reported · healthy breastfeeding women with healthy term babies Support for healthy breastfeeding mothers with healthy term babies (2022) · Cochrane | no estimate extracted | NR | No studies |
Intravenous ± oral steroids vs oral steroids alone Complete or partial remission · minimal change disease in adults with nephrotic syndrome Interventions for minimal change disease in adults with nephrotic syndrome (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Mobility outcome · adults following hip fracture surgery Interventions for improving mobility after hip fracture surgery in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Mobility outcome · adults following hip fracture surgery Interventions for improving mobility after hip fracture surgery in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Blastocyst‐stage vs cleavage‐stage embryo transfer Outcomes per couple · women and couples with subfertility Cleavage‐stage versus blastocyst‐stage embryo transfer in assisted reproductive technology (2022) · Cochrane | no estimate extracted | NR | No studies |
Virus vaccines vs placebo Mortality: vaccine related and all cause ‐ not reported · young, healthy men in a military facility Vaccines for the common cold (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Hydroxyurea and phlebotomy vs transfusion and chelation Quality of life · adults and children with sickle cell disease and an increased risk of stroke Hydroxyurea (hydroxycarbamide) for sickle cell disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Hydroxyurea vs observation Pain alteration · adults and children with sickle cell disease and an increased risk of stroke Hydroxyurea (hydroxycarbamide) for sickle cell disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Hydroxyurea vs observation Quality of life · adults and children with sickle cell disease and an increased risk of stroke Hydroxyurea (hydroxycarbamide) for sickle cell disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Hydroxyurea vs no hydroxyurea Pain alteration · adults and children with sickle cell disease Hydroxyurea (hydroxycarbamide) for sickle cell disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Hydroxyurea vs no hydroxyurea Life‐threatening illness · adults and children with sickle cell disease Hydroxyurea (hydroxycarbamide) for sickle cell disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Hydroxyurea vs no hydroxyurea Quality of life · adults and children with sickle cell disease Hydroxyurea (hydroxycarbamide) for sickle cell disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Comparison 1: Alpha‐blockers vs placebo Treatment efficacy ‐ treatment response, as measured by the Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85) Pharmacotherapy for post traumatic stress disorder (PTSD) (2022) · Cochrane | no estimate extracted | NR | No studies |
Comparison 3: MAOIs vs placebo Treatment efficacy ‐ treatment response, as measured by the Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85) Pharmacotherapy for post traumatic stress disorder (PTSD) (2022) · Cochrane | no estimate extracted | NR | No studies |
Comparison 5: SNRIs vs placebo Treatment efficacy ‐ treatment response, as measured by the Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85) Pharmacotherapy for post traumatic stress disorder (PTSD) (2022) · Cochrane | no estimate extracted | NR | No studies |
Medical abortion administered by nurses vs by doctors Nausea · women undergoing first trimester abortion Medical methods for first trimester abortion (2022) · Cochrane | no estimate extracted | NR | No studies |
Oral misoprostol vs vaginal misoprostol Women's dissatisfaction with the procedure · women undergoing first trimester abortion Medical methods for first trimester abortion (2022) · Cochrane | no estimate extracted | NR | No studies |
Oral misoprostol vs vaginal misoprostol Blood transfusion · women undergoing first trimester abortion Medical methods for first trimester abortion (2022) · Cochrane | no estimate extracted | NR | No studies |
Sublingual misoprostol vs vaginal misoprostol Blood transfusion · women undergoing first trimester abortion Medical methods for first trimester abortion (2022) · Cochrane | no estimate extracted | NR | No studies |
Mifepristone alone vs mifepristone/prostaglandin Nausea · women undergoing first trimester abortion Medical methods for first trimester abortion (2022) · Cochrane | no estimate extracted | NR | No studies |
Mifepristone alone vs mifepristone/prostaglandin Women's dissatisfaction with the procedure · women undergoing first trimester abortion Medical methods for first trimester abortion (2022) · Cochrane | no estimate extracted | NR | No studies |
Mifepristone alone vs mifepristone/prostaglandin Blood transfusion · women undergoing first trimester abortion Medical methods for first trimester abortion (2022) · Cochrane | no estimate extracted | NR | No studies |
Mifepristone (600 mg) plus prostaglandin vs mifepristone (200 mg) plus prostaglandin Women's dissatisfaction with the procedure · women undergoing first trimester abortion Medical methods for first trimester abortion (2022) · Cochrane | no estimate extracted | NR | No studies |
Oral misoprostol alone vs vaginal misoprostol alone Blood transfusion · women undergoing first trimester abortion Medical methods for first trimester abortion (2022) · Cochrane | no estimate extracted | NR | No studies |
Mifepristone (600 mg) plus prostaglandin vs mifepristone (200 mg) plus prostaglandin Blood transfusion · women undergoing first trimester abortion Medical methods for first trimester abortion (2022) · Cochrane | no estimate extracted | NR | No studies |
Misoprostol 800 µg plus mifepristone 200 mg vs misoprostol 400 µg plus mifepristone 200 mg Blood transfusion · women undergoing first trimester abortion Medical methods for first trimester abortion (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Pseudophakia vs aphakia Amblyopia ‐ not reported · children younger than two years of age with bilateral congenital cataracts Surgical interventions for bilateral congenital cataract in children aged two years and under (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Pseudophakia vs aphakia Retinal detachment ‐ not reported · children younger than two years of age with bilateral congenital cataracts Surgical interventions for bilateral congenital cataract in children aged two years and under (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Pseudophakia vs aphakia Reoperation rate ‐ not reported · children younger than two years of age with bilateral congenital cataracts Surgical interventions for bilateral congenital cataract in children aged two years and under (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Prone vs supine Mortality (respiratory events) ‐ not reported · acute respiratory distress in hospitalised infants and children (ARDs) Positioning for acute respiratory distress in hospitalised infants and children (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Supine vs good‐lung dependent Blood gases (PaCO2) ‐ not reported · acute respiratory distress in hospitalised infants and children (ARDs) Positioning for acute respiratory distress in hospitalised infants and children (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Supine vs good‐lung dependent Lung function (PaO2/FiO2 ratio) ‐ not reported · acute respiratory distress in hospitalised infants and children (ARDs) Positioning for acute respiratory distress in hospitalised infants and children (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Supine vs good‐lung dependent Oxygenation index (FiO2% X MPAW/PaO2) ‐ not reported · acute respiratory distress in hospitalised infants and children (ARDs) Positioning for acute respiratory distress in hospitalised infants and children (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Supine vs good‐lung dependent Potential adverse outcomes (episodes of apnoea) ‐ not reported · acute respiratory distress in hospitalised infants and children (ARDs) Positioning for acute respiratory distress in hospitalised infants and children (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Supine vs good‐lung independent Mortality (respiratory events) ‐ not reported · acute respiratory distress in hospitalised infants and children Positioning for acute respiratory distress in hospitalised infants and children (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Supine vs good‐lung independent Oxygen saturation (SaO2) ‐ not reported · acute respiratory distress in hospitalised infants and children Positioning for acute respiratory distress in hospitalised infants and children (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Supine vs good‐lung independent Blood gases (PCO2) ‐ not reported · acute respiratory distress in hospitalised infants and children Positioning for acute respiratory distress in hospitalised infants and children (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Supine vs good‐lung independent Lung function (PaO2/FiO2 ratio) ‐ not reported · acute respiratory distress in hospitalised infants and children Positioning for acute respiratory distress in hospitalised infants and children (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Supine vs good‐lung independent Oxygenation index (FiO2% X MPAW/PaO2) ‐ not reported · acute respiratory distress in hospitalised infants and children Positioning for acute respiratory distress in hospitalised infants and children (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Supine vs good‐lung independent Potential adverse outcomes (episodes of apnoea) ‐ not reported · acute respiratory distress in hospitalised infants and children Positioning for acute respiratory distress in hospitalised infants and children (2022) · Cochrane | no estimate extracted | NR | No studies |